Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Berit Gravdehaug"'
Autor:
Nina Strømsvik, Pernilla Olsson, Berit Gravdehaug, Hilde Lurås, Ellen Schlichting, Kjersti Jørgensen, Teresia Wangensteen, Tone Vamre, Cecilie Heramb, Lovise Mæhle, Eli Marie Grindedal
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background In South-Eastern Norway, genetic testing for BRCA1 and BRCA2 is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who
Externí odkaz:
https://doaj.org/article/7405b384fb0e4506be52a64cf8bd99d2
Autor:
Geeta Gulati, Siri L. Heck, Helge Røsjø, Anne H. Ree, Pavel Hoffmann, Tor‐Arne Hagve, Jon Norseth, Berit Gravdehaug, Kjetil Steine, Jürgen Geisler, Torbjørn Omland
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 11 (2017)
BackgroundAnthracyclines are associated with cardiotoxic effects. Cardiovascular biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may precede and predict the development of left ventricular impairment. The aim of
Externí odkaz:
https://doaj.org/article/fa4d943f76444ab399489cb7d2481be1
Autor:
Pernilla Olsson, Hilde Lurås, Teresia Wangensteen, Tone Bøe Aaman Vamre, Berit Gravdehaug, Eli Marie Grindedal, Lovise Maehle, Ellen Schlichting, Cecilie Heramb, Kjersti Jørgensen
Publikováno v:
Familial Cancer
Studies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered dire
Autor:
Nazli Bahrami, Hilde Presterud Ødegård, Jonas Christoffer Lindstrøm, Marie Loeng, Stephanie Geisler, Torben Lüders, Ingeborg Berge Vestøl, Annika Lorentzen, Belal Aljabri, Vahid Bemanian, Jürgen Geisler, Siri Engebretsen, Torill Sauer, Jan Øyvind Kvaløy, Joanna Majak Gundersen, Vessela N. Kristensen, Berit Gravdehaug
Publikováno v:
Future Oncology. 15:3675-3682
The aromatase inhibitor letrozole (Femar®/Femara®) and the aromatase inactivator exemestane (Aromasin®) differ in their biochemical effect on the aromatase enzyme. Letrozole is a competitive aromatase inhibitor while exemestane binds irreversibly
Autor:
Rahul Parulkar, Torill Sauer, Charles J. Vaske, V.N. Kristensen, B Aljabri, Vahid Bemanian, Torben Lüders, M Loeng, Jonas Christoffer Lindstrøm, Jürgen Geisler, Berit Gravdehaug, Nazli Bahrami
Publikováno v:
Cancer Research. 79:P3-06
Background. The NEO-LET-EXE trial examines the neoadjuvant use of sequential administration of the aromatase inhibitor letrozole (Femar / Femara) and the aromatase inactivator exemestane (Aromasin). Although both drugs nearly completely inhibit aroma
Autor:
Morten W. Fagerland, Geeta Gulati, Jeanette Schulz-Menger, Siri Lagethon Heck, Helge Røsjø, Pavel Hoffmann, Kjetil Steine, Jürgen Geisler, Anne Hansen Ree, Torbjørn Omland, Berit Gravdehaug, Albulena Mecinaj
Background: Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–related cardiac dysfunction. In the PRADA trial (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756db752292dc2b789651522e3139043
http://hdl.handle.net/10852/90187
http://hdl.handle.net/10852/90187
Autor:
Andliena Tahiri, Shakila Jabeen, Stephanie Geisler, Hilde Presterud Ødegård, Nazli Bahrami, Jürgen Geisler, Knut Selsås, Laurens Cornelus Reitsma, Vessela N. Kristensen, Berit Gravdehaug, Torill Sauer
Publikováno v:
Breast Cancer Research and Treatment
Purpose The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d163f40255dbfe673772e137cc20da22
http://hdl.handle.net/10852/91596
http://hdl.handle.net/10852/91596
Autor:
Nazli Bahrami, Shakila Jabeen, Torill Sauer, Hilde Presterud Ødegård, Stephanie Beate Geisler, Berit Gravdehaug, Laurens Cornelus Reitsma, Knut Selsås, Vessela Kristensen, Jürgen Geisler
Background: The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c18db6e02f7bce3cf37cfd2f780a7dda
https://doi.org/10.21203/rs.3.rs-62421/v1
https://doi.org/10.21203/rs.3.rs-62421/v1
Autor:
Jürgen Geisler, Daehoon Park, Torill Sauer, Berit Gravdehaug, Marie Loeng, Nazli Bahrami, Noriko Kanaya, Shiuan Chen, Gregory Chang
Publikováno v:
The Journal of steroid biochemistry and molecular biology. 200
The aromatase inhibitors (AIs), letrozole (Femar®/Femara®) and exemestane (Aromasin®), are widely used to treat estrogen receptor (ER) positive breast cancer in postmenopausal patients. In the setting of metastatic breast cancer, these drugs may b
Autor:
Eli Marie Grindedal, Kjersti Jørgensen, Pernilla Olsson, Berit Gravdehaug, Hilde Lurås, Jan Norum, Ellen Schlichting, Tone Vamre, Teresia Wangensteen, Cecilie Heramb, Lovise Mæhle
Background: Identification of a BRCA mutation in a breast cancer patient provides critical information both for treatment decisions and for prevention of new cancers. In South Eastern Norway, genetic testing of the BRCA genes has been mainstreamed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d667993b393d56994f4e840c80654559
https://doi.org/10.21203/rs.2.15182/v1
https://doi.org/10.21203/rs.2.15182/v1